Latest current cash for ASND: $810M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest current cash for ASND is $810M as of June 2026. That compares with $490M in the prior-year period — up 64.3% year over year. Investors often review this figure alongside Ascendis Pharma A/S's historical trend and sector peers before judging valuation or financial health.
Over the past year, ASND's current cash moved from $490M to $810M — a 64.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ascendis Pharma A/S's operating scale or balance-sheet position.
A current cash figure of $810M for ASND is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting ASND's current cash ($810M), review year-over-year change from $490M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Ascendis Pharma A/S's current cash against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.